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Abstract
Glucokinase (GCK) catalyzes the rate-limiting step of glucose catabolism in the pancreas, where it functions as the body’s
principal glucose sensor. GCK dysfunction leads to several potentially fatal diseases including maturity–onset diabetes of the
young type II (MODY-II) and persistent hypoglycemic hyperinsulinemia of infancy (PHHI). GCK maintains glucose
homeostasis by displaying a sigmoidal kinetic response to increasing blood glucose levels. This positive cooperativity is
unique because the enzyme functions exclusively as a monomer and possesses only a single glucose binding site. Despite
nearly a half century of research, the mechanistic basis for GCK’s homotropic allostery remains unresolved. Here we explain
GCK cooperativity in terms of large-scale, glucose-mediated disorder–order transitions using 17 isotopically labeled
isoleucine methyl groups and three tryptophan side chains as sensitive nuclear magnetic resonance (NMR) probes. We find
that the small domain of unliganded GCK is intrinsically disordered and samples a broad conformational ensemble. We also
demonstrate that small-molecule diabetes therapeutic agents and hyperinsulinemia-associated GCK mutations share a
strikingly similar activation mechanism, characterized by a population shift toward a more narrow, well-ordered ensemble
resembling the glucose-bound conformation. Our results support a model in which GCK generates its cooperative kinetic
response at low glucose concentrations by using a millisecond disorder–order cycle of the small domain as a ‘‘time-delay
loop,’’ which is bypassed at high glucose concentrations, providing a unique mechanism to allosterically regulate the
activity of human GCK under physiological conditions.
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Introduction
Human pancreatic glucokinase (GCK) is the body’s principal
glucose sensor [1]. GCK is a 52 kDa monomeric enzyme that
catalyzes the formation of glucose-6-phosphate from glucose and
ATP [2]. This chemical transformation represents the rate-limiting
step of glucose catabolism in the pancreas, allowing GCK activity
to regulate the rate at which insulin is secreted from b-cells [3–5].
The importance of this enzyme in maintaining glucose homeo-
stasis is emphasized by several disease states associated with GCK
dysfunction. Loss-of-function mutations, of which more than 600
have been described, cause either maturity onset diabetes of the
young type II (MODY-II) or permanent neonatal diabetes mellitus
(PNDM) [6]. A small number of gain-of-function mutations have
also been identified in patients with the potentially fatal disease,
persistent hypoglycemic hyperinsulinemia of infancy (PHHI) [7–
19]. Functional characterization indicates that most PHHI-
associated variant enzymes display a reduced level of positive
cooperativity toward glucose. Interestingly, many of the PHHI-
associated substitutions co-localize to a common region of the
GCK scaffold that is distant from the active site [7–19]. In recent
years, pharmaceutical research has directed significant efforts
toward developing synthetic allosteric activators that target GCK
as a strategy to lower blood glucose levels in type 2 diabetic
patients [20]. At least one GCK activator has advanced to phase II
clinical trials as an antidiabetic agent, yet the functional role and
molecular basis of action of such molecules is poorly understood
[21]. Similarly, the mechanism of hyperactivity associated with
PHHI-linked GCK variants is unclear.
GCK’s unique kinetic features are responsible for its physio-
logical role in maintaining glucose homeostasis. The steady-state
velocity shows a sigmoidal dependence upon glucose concentra-
tion, with a Hill coefficient of 1.7 [2]. This positive cooperativity
enables GCK to sensitively respond to small perturbations in
blood glucose concentrations, whereby the midpoint of this steady-
state response, K0.5, approximates physiological blood sugar levels
(4–10 mM). The kinetic cooperativity of GCK is mechanistically
distinct from other modes of allostery, which involve polypeptide
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oligomerization or require multiple ligand binding sites [22–25].
Two theoretical mechanisms—the ligand-induced slow transition
(LIST) and mnemonic models—have been put forth to explain
kinetic cooperativity in monomeric GCK [26,27]. In both models,
cooperativity is postulated to result from slow conformational
transitions that accompany glucose binding and/or product
release. The models differ, however, in the relative degree of
conformational heterogeneity displayed by the enzyme at various
stages along the reaction coordinate. According to the LIST
mechanism, two separate catalytic cycles are possible resulting
from two distinct conformations of the enzyme. In contrast, the
mnemonic model postulates a single catalytically active enzyme
conformation with the ability to ‘‘remember’’ its active state for
only a short period of time following turnover. Although data have
accumulated over the years in support of each mechanism, a
consensus has yet to be reached [28–33].
X-ray crystallographic structures reveal that GCK adopts a
prototypic hexokinase fold, consisting of a small and large domain
separated by a variable opening angle dependent upon substrate
association (Figure 1A) [28]. The kinetic mechanism of GCK is
strictly ordered [2], with glucose binding first, accompanied by a
large structural rearrangement from an open to a closed structure
(Figure 1B). Binding of ATP does not induce significant additional
changes to the structure of the glucose-bound state (Figure 1C)
[34]. The crystal structures also identify a common binding site for
synthetic GCK activators at a location within the small domain
that is approximately 20 A˚ removed from the glucose binding site.
Differences observed between available crystal structures
demonstrate the ability of GCK to sample discrete conformations,
but they do not explain the dynamic basis of allosteric regulation
as set forth in the LIST and mnemonic models [28,29,34–38].
Herein, we describe the results of the first investigation of the
functional dynamics of GCK at atomic detail by high-resolution
NMR of specifically labeled side chains. We characterize the
conformational dynamics of the wild-type enzyme as it progresses
along the reaction coordinate and explain the molecular
mechanism of kinetic cooperativity. We also uncover the
molecular basis of activation observed in PHHI-associated variants
or when a synthetic activator associates with the enzyme. Our
findings suggest a model for GCK cooperativity involving a slow
disorder–order cycle of an intrinsically disordered domain that is
operational under low glucose concentrations but that is bypassed
at elevated glucose concentrations.
Results and Discussion
The Small Domain of GCK Is Intrinsically Disordered
The large size and dynamic nature of GCK, combined with the
poor spectral dispersion even upon perdeuteration, prevented the
use of traditional NMR approaches for backbone resonance
assignment and structural analysis [32]. Instead, we focused on
selected side chains only, a strategy that has proven effective for
studies of other challenging protein systems and large complexes
[39,40]. For this purpose, we introduced 13C spin probes in the
Cd1 methyl groups of 17 isoleucine side chains and 15N spin
probes at the Ne sites of three tryptophan side chains [39–41]. The
labeled residues are quite uniformly distributed throughout the
enzyme’s structure. The large domain contains one Trp and 10 Ile
residues, while two Trp and seven Ile residues reside in the small
domain (red and yellow spheres in Figure 1A–C). Together these
probes permit the study of internal dynamics throughout the
protein. Importantly, the methyl resonances can retain narrow line
widths even in high-molecular weight proteins through the methyl-
TROSY effect manifested in the 2D 1H-13C HMQC experiment
used here [39,40]. Site-specific assignment of Ile and Trp
resonances was achieved by single-site substitutions with Val and
Phe, respectively, followed by the recording of 2D 1H-13C HMQC
and 1H-15N HSQC spectra to identify missing cross-peaks (Figure
S1).
To achieve a global portrait of the enzyme’s structure and
dynamics prior to glucose association, we collected 1H-13C
HMQC spectra of 13CH3-Ile labeled GCK. The
1H-13C HMQC
of unliganded GCK displays a high degree of cross-peak overlap
and heterogeneous peak intensities (Figures 1D and S2). This
behavior is consistent with previously reported, unassigned
1H-15N TROSY spectra of GCK specifically labeled on Ile
backbone atoms [32]. Nine Ile residues located in the large
domain and two Ile side chains situated in the small domain are
observable in unliganded GCK. The 2D 1H-15N HSQC
spectrum of unliganded 15N-Trp labeled GCK reveals only a
single cross-peak. Mutagenesis demonstrated that this cross-peak
is dominated by contributions from W167 (Figure S3). Notably,
the only small domain residues observable in the unliganded
spectra—I159, I163, and W167—all reside in a loop that is
absent in the X-ray structure of unliganded GCK. The sharp
cross-peaks originating from these three residues, along with the
nearly degenerate chemical shifts of the Ile 159 and 163, reflect
the presence of extensive rapid motional averaging and indicate
that this loop is disordered, both in the crystal and in solution
(Figure S4) [42,43].
To investigate whether the absence of the resonances of five
isoleucines belonging to the small domain results from motions of
these side chains occurring on the intermediate exchange regime
(ms – ms time scale), we collected 1H-13C HMQC spectra of
unliganded GCK at variable temperatures. Across a range of
temperatures (283–313 K) compatible with retention of enzyme
activity, no additional cross-peaks were observed that could be
attributed to the five missing small domain isoleucine side chains
(Figure S5). We tested whether the five missing isoleucine cross-
Author Summary
Glucokinase is a key metabolic enzyme that functions as
the body’s principal glucose sensor. Glucokinase regulates
the rate at which insulin is secreted by the pancreas by
using a unique but poorly understood cooperative kinetic
response to increasing glucose concentrations. The phys-
iological importance of this enzyme is underlined by the
fact that mutations in the glucokinase gene lead to
maturity-onset diabetes of the young type II (MODY II),
permanent neonatal diabetes mellitus (PNDM), and hypo-
glycemic hyperinsulinemia of infancy (HI). In this study, we
use cutting-edge high-resolution nuclear magnetic reso-
nance methods to understand how the kinetic properties
of glucokinase contribute to glucose homeostasis. We also
seek to understand how a class of recently discovered
small-molecule drugs, which hold promise as therapeutics
for type 2 diabetes, function to enhance glucokinase
activity. Our results suggest that glucokinase samples a
range of conformational states in the absence of glucose.
However, in the presence of glucose or a small-molecule
activator, the enzyme population shifts towards a more
narrow, well-structured ensemble of states. Our findings
provide a new model for glucokinase cooperative kinetics,
which relies on a slow order–disorder transition in
response to glucose concentrations. These results also
reveal a universal mechanism of glucokinase activation,
which may inform the development of new antidiabetic
agents.
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peaks might reside in the intrinsically disordered side chain region
of the 1H-13C HMQC spectrum, underneath the sharp, intense
peaks of I159 and I163, by constructing a variant in which I159
and I163 were replaced with leucines. These substitutions had a
minimal impact upon the kinetic properties of the enzyme (Table
S1); however, the removal of I159 and I163 did not eliminate all
peak intensity in the region of the spectrum where disordered side
chains are expected. Therefore, residual intensity observed in the
I159L–I163L double variant could stem from some of the
remaining isoleucine side chains in the small domain (Figure
S6). Together these results show that the majority of the
isoleucines of the small domain are subject to conformational
exchange with an exchange rate kex that fulfills the NMR
coalescence condition kex<2.2Dv, where Dv is the chemical shift
change between conformational substates of unliganded GCK. At
least two isoleucines, I159 and I163, remain fully disordered in the
unliganded form of GCK.
Glucose Association Induces Ordering of the Small
Domain
Upon addition of glucose, the intensity of the intrinsically
disordered region of the 1H-13C HMQC spectrum decreases and
new cross-peaks originating from I110, I126, I130, I189, and I211
become clearly visible (blue peaks in Figure 1E). In contrast,
residues in the large domain are much less affected by glucose
binding (gray peaks). In the presence of glucose, the cross-peaks of
I159 and I163 dramatically increase their line widths and shift to
new positions (Figures 1E and S2), reflecting the formation of the
151–179 b-hairpin, a well-defined structural element in the crystal
structure 1V4S [28]. In the 1H-15N HSQC spectrum of the 15N-
tryptophan-labeled GCK–glucose complex, three well-resolved
cross-peaks corresponding to W99, W167, and W257 are observed
(Figure 2G), consistent with the glucose-induced structural
organization observed in the 1H-13C HMQC spectra of 13CH3-
Ile labeled enzyme. Addition of the ATP analogue AMP–PNP to
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the binary complex perturbs the spectrum only slightly, indicating
that AMP–PNP weakly impacts the structure and dynamics of the
binary complex (Figure 1F).
Molecular Basis of Activation for PHHI-Associated
Substitutions and Therapeutic Agents
Although PHHI is usually associated with single amino acid
replacements, we employed our previously identified hyperactive
quadruple variant to fully characterize the structural and
functional impacts of activating mutations [44]. This hyperactive
variant contains a redesigned a13-helix with sequence ALIAAAV.
Similar to other activating PHHI-linked variants, the a13-helix
variant displays a decreased glucose K0.5 value, a reduced level of
cooperativity, and an increased equilibrium affinity for glucose
compared to wild-type GCK [44]. Specifically, the glucose KD
value of the a13-helix variant is 50 mM, a value similar to glucose
Km values of the noncooperative GCK isozymes, hexokinases
I–III. In contrast to wild-type GCK, the 1H-13C HMQC of the
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Figure 2. Structural, dynamic, and kinetic descriptions of GCK activating states. (A) Crystal structure of the GCK–activator complex
depicting the spatial vicinity of the regions involved in allosteric communication. The 151–179 b-hairpin is shown in magenta, the a13-helix in blue,
and the Cas of Ile-159, Ile-163, and Trp-167 residues are colored in red (Ile) and yellow (Trp) spheres. Glucose is colored in green, and the synthetic
allosteric activator in cyan. The side chain of Lys-169, which is represented by magenta sticks, is hydrogen-bonded to O6 of glucose. Val-452 and Ile-
159 side chains are located within 5 A˚ of each other and of the activator thiazole ring. (B) Kinetic response of the a13-helix variant (green), and wild-
type GCK in the absence (blue) and presence (red) of saturating activator (see Table S1). 2D 1H-13C HMQC spectra of (C) unliganded GCK, (D) activator-
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details, see Figure S3).
doi:10.1371/journal.pbio.1001452.g002
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unliganded a13-helix variant displays cross-peaks originating from
Ile residues in both the small and large domains (Figure 2E).
Under saturating glucose conditions, the a13-helix variant exhibits
a spectrum that closely resembles the wild-type glucose-bound
spectrum (Figure S7). These spectral characteristics are not specific
to the hyperactive a13 variant, as similar effects were observed
with the single-site activating variant, S64P (Figure S8B). In
general, the 1H-13C HMQC spectra of activated variants reveal
varying degrees of structural stabilization relative to the wild-type
enzyme. We observed a correlation between increases in glucose
affinity caused by individual activating GCK variants, a systematic
sharpening of cross-peaks, and the appearance of a larger number
of resolved cross-peaks in the 1H-13C HMQC spectra in their
unliganded state (Figure S8). These data demonstrate that
activating PHHI-associated substitutions alter enzyme dynamics
and promote a conformational ensemble that more closely
resembles the glucose-bound state.
Binding of the allosteric activator, which reduces the glucose
K0.5 value and eliminates cooperativity, induces changes in the 2D
1H-13C HMQC spectrum similar to that produced by activating
variants (Figure 2). Well-dispersed cross-peaks originating from Ile
residues in both the large and small domain are observed in the
presence of the activator. The only differences between the NMR
spectra of glucose-bound GCK in the absence and presence of the
activator arise from residues near the activator binding site, such
as I211 (Figure S9), suggesting local perturbations only. From
these data, we conclude that allosteric activators stabilize the small
domain and alter GCK dynamics. Our results also demonstrate
that small-molecule-mediated GCK activation does not require
prior formation of the binary GCK–glucose complex, a finding
that could have important therapeutic implications.
Direct Mode of Communication between the Allosteric
and Active Sites: Stabilization of the a13-Helix Leads to
Folding of the 151–179 Loop
The 151–179 loop is disordered in unliganded wild-type GCK, as
evidenced by the fact that the chemical shifts and peak intensities of
I159, I163, and W167 fall within the disordered side chain region
(Figure S4). This loop becomes structured in the unliganded a13-
helix variant as shown by the 2D 1H-15N HSQC and 2D 1H-13C
HMQC spectra in Figure 2E and H. Notably, the chemical shift of
W167 in the unliganded a13-helix variant is identical to that
observed in the wild-type GCK-glucose complex (Figure 2G and
H), indicating that the loop conformation adopted by the variant is
similar to that produced upon glucose binding. The crystal structure
reveals a possible mode of communication between the activator,
the a13-helix, and the 151–179 loop (Figure 2A) [28]. One face of
the activator binding site is comprised of the a13-helix residues
V452, V455, and A456, and two of these residues, V452 and A456,
interact with the loop residue I159. In the presence of the activator,
or when an activating substitution is introduced into the a13-helix,
the interactions between I159, V452, and A456 are stabilized. In
turn, this stabilization is relayed to the glucose binding site via two
additional loop residues, T168 and K169, which form hydrogen
bonds with the O1 and O6 atoms of bound glucose. Structural
organization of either the a13-helix or the 151–179 loop can be
achieved by glucose binding, activator association, or a hyperactive
substitution.
Our Data Reveal a Universal Mechanism of GCK
Activation
PHHI variants or the allosteric activator promote a population
shift toward a more structured state, which involves a major
reorganization of the small domain. This effect, which is evidenced
by increased spectral dispersion and loss of line broadening
compared to the unliganded wild-type enzyme, abrogates kinetic
cooperativity. The differential glucose binding affinities of wild-
type GCK and the a13-helix variant (KD = 5 mM and 50 mM,
respectively) suggest that a substantial thermodynamic barrier
separates the closed GCK conformation from the unliganded
state. In the wild-type enzyme, this barrier is overcome by glucose
binding, which triggers the disorder–order transition. In an
activated variant, or in the presence of a synthetic activator, the
small domain is stabilized, which decreases the free energy penalty
of the conformational change and allows glucose binding energy to
manifest itself in the form of a lower KD value. The differential
glucose binding affinities of wild-type and activated GCK also
suggest that the high-affinity conformation represents #1% of the
total unliganded ensemble.
A Refined Model for GCK Cooperativity
The experimental data presented here provide direct evidence
that the small domain of GCK is highly dynamic in the absence of
ligand. Some evidence of GCK structural plasticity has emerged
from X-ray structures determined in the presence and absence of
various ligands; however, since crystal structures represent high-
resolution snapshots of protein states, they neither reveal time-
scale information nor how different states are dynamically related
to each other. Optical spectroscopy, on the other hand, provides
time-scale information at single sites without reporting on local
structure. Indeed, the application of transient state fluorescence
spectroscopy to GCK revealed the existence of glucose-induced
structural rearrangements that span multiple time scales, but these
studies failed to provide a unified, structure-based mechanism of
GCK cooperativity [45–48]. Here we used all native Ile and Trp
side chains to probe the structural-dynamic behavior of GCK at
20 different sites distributed throughout the protein. These data,
obtained in solution under physiological conditions in the absence
and presence of glucose and activator, provide temporal informa-
tion for wild-type GCK and its variants with high spatial
resolution. Based on this new type of information, we propose a
refined model for allostery in monomeric GCK.
The model that emerges from our data demonstrates that GCK
cooperativity may result from dynamic structural modulations of
the intrinsically disordered small domain. In the absence of ligand,
the enzyme exists as an ensemble of conformations, which
interconvert on a millisecond time scale that coincides with
enzyme turnover (kcat,60 s21) (Figure 3). Upon glucose associa-
tion the small domain becomes ordered, as reflected in the
sharpening of the NMR resonances and the increase of chemical
shift dispersion of Ile residues. After formation of the GCK–
glucose binary complex, ATP binds and catalysis proceeds with
little additional reorganization. Following product release, ordered
unliganded GCK persists until, on the millisecond time scale, the
small domain undergoes an order–disorder transition, allowing
access to a ‘‘time delay loop.’’ Under low glucose concentrations,
the delay loop is operational, leading to slow turnover and kinetic
cooperativity (Figure 3, red). Under high glucose concentrations,
or when GCK is activated, the delay loop is effectively bypassed,
turnover is fast, and cooperativity is eliminated (Figure 3, green).
The putative involvement of slow conformational changes in the
generation of kinetic cooperativity in enzymes has long been
appreciated [49]. In the case of GCK, the generation of a sigmoidal
steady-state response, which is key to this enzyme’s sensitivity to
oscillating physiological glucose levels, requires a time delay slower
than 1/kcat. The absence of resonances from Ile residues located in
the small domain prevents quantitative analysis of the underlying
Glucokinase Dynamics and Kinetic Cooperativity
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rate constants associated with the disorder–order transition.
However, typical Ile and Trp side-chain chemical shift ranges
point to a rate constant kex between 5 s
21 and 100 s21 in order to
explain the disappearance of the cross-peaks from the small domain
by coalescence. This disorder–order transition rate satisfies the
conditions needed to account for the existence of kinetic
cooperativity in GCK [26,27]. Protein structural organization
occurring in the millisecond time regime is not uncommon [50],
and here this phenomenon appears to contribute to the generation
of GCK cooperativity. As with other intrinsically disordered
proteins [51,52], it is possible that the dynamic nature of the small
domain also plays a role for the emergence of new functional
attributes, including regulation of GCK activity by multiple
interacting partners [53–55] and posttranslational events [56,57].
Materials and Methods
Protein Expression and Purification
Recombinant human pancreatic GCK was produced as an N-
terminal hexa-histidine-tagged polypeptide in Escherichia coli strain
BL21(DE3). Bacterial cultures were inoculated to an initial
OD600 nm of 0.06 and were grown at 37uC in minimal medium
supplemented with ampicillin (150 mg/mL), thiamine hydrochlo-
ride (25 mg/mL), 15NH4Cl (1 g/L), Ca(OH)2 (0.1 mM), MgSO4
(1 mM), and glycerol (1%) (w/v). When the OD600 nm reached
0.85, IPTG (1 mM) was added to induce gene expression and
growth was continued for 12 h. The specific incorporation of 15N
and 13C labels in the Trp and Ile residues, respectively, was
achieved following the protocols by Muchmore et al. [41] and
Tugarinov et al. [39]. Cells were harvested by centrifugation at
8,000 g, and 5 g of wet cell pellet was resuspended in 17 mL of
buffer A containing HEPES (50 mM, pH 7.6), KCl (50 mM),
imidazole (40 mM), dithiothreitol (10 mM), and glycerol (25% w/
v). Cells were lysed using a French Press and subjected to
centrifugation at 25,000 g at 4uC for 1 h. The supernatant was
immediately loaded onto a 5 ml HisTrap Fast Flow Affinity
Column (GE Healthcare) previously equilibrated in buffer A.
Following loading, the column was washed with 10 column
volumes of buffer A followed by 5 columns of buffer A containing
65 mM imidazole. GCK was eluted with buffer A containing
250 mM imidazole, and the enzyme was dialyzed at 4uC against
1L of potassium phosphate buffer (25 mM, pH 8), containing KCl
(25 mM) and dithiothreitol (10 mM). GCK was then concentrated
to ,600 mM using an Amicon centrifugal concentrator
(MWCO = 10,000). Protein was injected onto a Superdex 200
16/60 gel filtration column (Amersham-Pharmacia) pre-equili-
brated with potassium phosphate buffer (25 mM, pH 8.0),
containing KCl (25 mM) and DTT (10 mM). The gel filtration
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Figure 3. Mechanism of GCK kinetic cooperativity. (A) The small domain of unliganded GCK is intrinsically disordered, giving rise to a broad
conformational ensemble. (B) Glucose binding, activator binding, or an activating PHHI-associated mutation promotes folding of the disordered
regions in the small domain, narrowing the conformational distribution. Upon formation of the GCK–glucose binary complex, ATP binds and catalysis
proceeds with little additional reorganization. (C) Following product release, ordered unliganded GCK persists until the small domain undergoes an
order–disorder transition on the millisecond time scale, allowing access to the ‘‘time delay loop’’ (red): Under low glucose concentrations, the delay
loop is operational, leading to slow turnover and kinetic cooperativity. Under high glucose concentrations (or when GCK is activated), the delay loop
is effectively bypassed, turnover is fast, and cooperativity is eliminated (green).
doi:10.1371/journal.pbio.1001452.g003
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column was run at a flow rate of 0.12 mL/min, and fractions that
contained the highest A280 nm readings were pooled and used
immediately in the NMR experiments.
Site-Directed Mutagenesis
Site-directed mutagenesis was performed using the QuikChange
protocol (Stratagene). Mutagenesis reactions contained human glk
template DNA (400 ng), Pfu Turbo enzyme (2.5 units), cloned Pfu
Turbo reaction buffer (16), and mutagenic primers (125 ng).
Enzyme Assays
GCK activity was measured spectrophotometrically at 340 nm
by coupling the production of ADP to the oxidation of NADH via
the combined action of pyruvate kinase and lactate dehydroge-
nase. Assays were conducted at 25uC in reaction mixtures
containing HEPES (250 mM, pH 7.6), KCl (50 mM), NADH
(0.25 mM), dithiothreitol (10 mM), pyruvate kinase (15 units),
lactate dehydrogenase (15 units), ATP (0.1–50 mM), MgCl2 (1.1–
51 mM), and glucose (0.05–100 mM). Data were fitted to the Hill
equation or the Michaelis-Menten equation depending on the
substrate under investigation. Assays were initiated by the addition
of ATP and were conducted in duplicate for each substrate
concentration. The kinetic constants reported are the average of
data obtained from at least two independent preparations of
enzyme. Assays were conducted before and after NMR measure-
ments to verify retention of enzyme activity during the time course
of the experiment.
NMR Data Collection, Processing, and Resonance
Assignment
All NMR data were collected with a Bruker Avance III
spectrometer operating at 800 MHz proton field and equipped
with a TCI cryogenic probe. The GCK NMR samples were
prepared in potassium phosphate buffer (25 mM, pH 8.0),
containing KCl (25 mM), DTT (10 mM), deuterated glycerol
(5% v/v), and D2O (10% v/v). For all experiments of glucose-
bound GCK, glucose was added to a total concentration of
200 mM. 1H-13C HMQC experiments were recorded as matrices
of 20486390 (in Figure 1) or 20486256 (in Figure 2) complex data
points. Unless otherwise stated, 1H-15N HSQC experiments were
recorded as matrices of 20486128 complex data points. All
spectra were apodized with a cosine function in each dimension
prior to zero-filling. NMR data processing and spectral analyses
were performed with NMRPipe [58] and the CCPN-Analysis
software [59]. As a control, the enzymatic activity of GCK was
measured before and after each NMR experiment.
Site-specific assignments of Ile and Trp resonances were mainly
achieved by single-site substitution with Val/Leu and Phe,
respectively, followed by the recording of 2D 1H-13C HMQC and
1H-15N HSQC spectra to identify missing cross-peaks (Figure S7).
Assignments of Ile residues in the a13-helix variant could be directly
transferred from their wild-type assignments due to identical peak
positions, except for I159 and I163, which were assigned by site-
directed mutagenesis. Ile residues in the GCK–activator complex
were assigned based on identical cross-peak positions with respect to
the wild-type spectrum. Assignments for W99, W167, and W257 in
wild-type GCK and for W167 in the a13-helix variant were
performed by individually replacing Trp by Phe.
Supporting Information
Figure S1 Illustration of the assignment procedure for Ile cross-
peaks of GCK. The spectrum of wild-type GCK in the glucose-
bound state (black) is superimposed on the spectrum of the I351V
variant (red). The disappearance of the cross-peak due to I351 in
the mutant is followed by a small chemical shift change of I348
due to their close spatial proximity.
(EPS)
Figure S2 Distribution of NMR cross-peak line widths and
intensities of GCK in the absence and presence of glucose. The 2D
1H-13C HMQC cross-peaks of unliganded GCK display a broad
range of line widths along the 13C dimension between 10 and
115 Hz. (A) Addition of glucose narrows the line width distribution
to a range of 20–60 Hz. (B) Unliganded GCK shows a
heterogeneous distribution of 1H-13C HMQC cross-peak intensi-
ties, which becomes more homogeneous upon glucose addition.
Labels indicate the intensities and line widths of I159 and I163
signals as they are the strongest and sharpest cross-peaks in the
absence of glucose, which is consistent with their high internal
mobility. The 1H-13C HMQC experiments were recorded with t1-
evolution times up to 56.59 ms. The spectra were zero-filled to
8,192 data points in both dimensions and processed without
apodization.
(EPS)
Figure S3 Trp167 is the major contributor to the dominant
cross-peak in the 1H-15N HSQC spectrum of unliganded GCK.
One-dimensional cross-sections along the v2 (
1H) dimension
corresponding to a v1 (
15N) frequency of 129 ppm, extracted
from 2D 1H-15N HSQC spectra of wild-type GCK (black), W99F
(blue), W257F (green), and W167F variant (red). All 1H-15N
HSQC spectra were recorded as matrices of 2048668 complex
data points and zero-filled to 20486128 data points. The NMR
samples consisted of 370, 330, 532, and 257 mM protein solution
for W167F, W99F, W257F, and wild-type GCK, respectively,
labeled specifically with 15N at all tryptophan side chains. The
spectra were uniformly scaled by factors of 1.12 (W99F), 2.04
(wild-type), and 0.69 (W257F) in order to account for the different
sample concentrations relative to the W167F sample.
(EPS)
Figure S4 Ile and Trp side-chain chemical shifts reflect the
disordered nature of unliganded GCK. (A) The 13C and the 1H
chemical shifts of I159 and I163 (Cd1 and Hd1) observed in the
1H-13C HMQC spectrum of unliganded GCK are consistent with a
disordered loop, as evidenced by comparison with the 13C and 1H
chemical shifts of Ile 13Cd1-1Hd1 spin pairs of denatured or
intrinsically disordered proteins deposited in the Biological Magnetic
Resonance Data Bank or BMRB (solid red circles). The mean of the
BMRB distribution of disordered Ile 13Cd1-1Hd1 is shown as a solid
green circle, with the error bars corresponding to the standard
deviations along the 13C and 1H dimensions:
,d(13C).= 12.68960.449 ppm and ,d(1H).= 0.78560.054 ppm.
The dark blue circle represents an outlier, which is .11 standard
deviations away from the average Ile 13Cd1 chemical shift belonging to
BMRB entry 7279 and which was excluded from analysis. The small
blue dots represent Ile 13Cd1-1Hd1 chemical shifts of all BMRB entries,
and their average is indicated by the cyan open circle. (B) The 15Ne1
and the 1He1 chemical shifts of the Trp167 side chain observed in the
1H-15N HSQC spectrum of unliganded GCK are also consistent with
a disordered region. The solid green circle shows the mean of the
BMRB distribution of disordered Trp 15Ne1-1He1 along the 15N
and 1H dimensions: ,d(15N).= 129.45960.118 ppm and
,d(1H).= 10.08760.016 ppm. The dark blue circle represents an
outlier, which is .38 standard deviations away from the average Trp
1He1 chemical shift belonging to BMRB entry 15201 and which was
excluded from analysis. The small blue dots represent Trp 15Ne1-1He1
chemical shifts of all BMRB entries, and their average is indicated by
the cyan open circle. The red solid circles represent Trp 15Ne1-1He1
Glucokinase Dynamics and Kinetic Cooperativity
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chemical shifts of denatured or intrinsically disordered proteins
deposited in the Biological Magnetic Resonance Data Bank or BMRB.
(A and B) Chemical shifts for denatured or intrinsically disordered
proteins were obtained from a subset of all BMRB entries marked as
‘‘unfolded.’’ The analysis was restricted to those entries that (i) have
assigned side-chain Ile 1Hd1-13Cd1 and Trp 15Ne1-1He1 chemical
shifts and (ii) have local secondary structure propensity scores (SSP) at
the isoleucine and tryptophan sites between 20.3 and 0.3 [60]. The
second criterion, which ensures that protein regions with relatively high
(.30%) propensities for a13-helix or b-strand propensities are
excluded from analysis, was calculated as the SSP averaged over
residues (i21, i, i+1), where i is Trp or Ile. This left three BMRB entries
(15201, 15225, and 7279) for Ile 1Hd1-13Cd1 and two entries (15201
and 15225) for Trp 15Ne1-1He1.
(EPS)
Figure S5 The influence of temperature on the 2D 1H-13C
HMQC of unliganded GCK. Comparison of high-temperature
(313K, A) with low-temperature (283K, B) 1H-13C HMQC of
unliganded GCK. A decrease in signal intensity and disappearance
of cross-peaks is observed upon decreasing temperature by 30uC.
(EPS)
Figure S6 Residual intensity exists underneath the sharp peaks
of I159 and I163 and displays glucose dependence. Superposition
of the first increment of 450 mM I159LI163L (red) 2D 1H-13C
HMQC with the 400 mM wild-type GCK (blue) in the unliganded
(A) and glucose-bound form (B). In unliganded GCK (A, blue
spectrum) the intensity of the intrinsically disordered side-chain
region is dominated by I159 and I163. Substitution of these
isoleucine residues with leucine revealed the existence of residual
intensity in this region attributable to some or all of the other
isoleucine residues located in the small domain (A, red, spectrum).
Addition of saturating glucose to the variant lacking reporters in
the disordered loop region (I159LI163LGCK, B, red spectrum)
decreased further the intensity of the intrinsically side chain region
compared to the wild-type GCK (B, blue spectrum). The data
were recorded as matrices of 1024664 (wild-type) and 10246350
(I159LI163L GCK) complex data points and multiplied by a
squared cosine apodization function.
(EPS)
Figure S7 The hyperactive a13-helix variant of GCK adopts a
virtually identical conformation as wild-type GCK upon glucose
binding. (A) Overlay of the 2D 1H-13C HMQC spectrum of
glucose-bound a13-helix variant (red) and wild-type GCK (black)
upon addition of 200 mM glucose. The only significant difference
in the spectra concerns I211, which is present as a very weak cross-
peak in wild-type GCK. (B) Superposition of 2D 1H-13C HMQC
spectrum of unliganded a13-helix variant (red) and glucose-bound
GCK (black). Note that both I163 and I159 appear as peak pairs,
with one of the peaks each coinciding with the peak positions of
unliganded wild-type GCK. The other two peaks of I159 and
I163, marked with a prime, appear at positions that are further
away from the disordered region, indicating a certain degree of
ordering.
(EPS)
Figure S8 Correlation between glucose binding affinity, cross-
peak dispersion, and line widths for different activated states of
GCK. (A) The 2D 1H-13C HMQC spectrum of unliganded GCK
displays significant spectral overlap and broad cross-peaks. (B and
C) Activating states of GCK show increased affinities for glucose
binding and display a gradual increase in cross-peak dispersion
and peak narrowing. Wild-type GCK has a KD, glucose of 5 mM,
S64P variant has an intermediate KD, glucose of 120 mM, and the
a13-helix variant displays a KD, glucose of 50 mM.
(EPS)
Figure S9 NMR characterization of activator binding to the
binary GCK-glucose complex and glucose titration to GCK. (A)
Activator binding to the binary GCK–glucose complex induces
only local chemical shift changes without perturbing the
conformation of the binary state. 2D 1H-13C HMQC of GCK–
glucose binary complex in the absence (black) and presence (red) of
saturating activator. An arrow indicates a significant chemical shift
change induced by activator binding. The most affected residues
(I159, I404, and I211) are labeled in red and are located in close
proximity to the allosteric binding site. I211 interacts directly with
the activator. I159 is located within 5.8 A˚ from the N of the
thiazole ring of the activator, and I404 is located within 9 A˚ from
the methyl carbon of imidazole ring of the activator molecule. (B)
2D 1H-13C HMQC of GCK in absence of glucose (left) and
displaying the cross peak of I436 (right) for clarity. (C) 2D 1H-13C
HMQC of GCK in the presence of physiologically relevant
glucose concentrations (5mM) (left) where the cross-peak of I436
(right) displays two population corresponding to the unbound and
glucose bound fractions, respectively. (D) 2D 1H-13C HMQC of
GCK in presence of saturating amounts of glucose (left) where the
I436 cross-peak (right) is represented just by the glucose-bound
population. The results of (B, C, D) reveal that the unliganded and
glucose-bound states of GCK are in slow exchange on the NMR
time scale.
(EPS)
Table S1 aKinetic parameters of wild-type and variants of GCK
used in this study.
(DOCX)
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